Edesa Biotech
Biopharma, Biotechnology, Pharmaceutical · 20 employees
Edesa Biotech, Inc. (Nasdaq: EDSA) is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a
Funding history
- Funding Round — $15.0M — Feb 2025
- Funding Round — Undisclosed — Apr 2022
Recent signals
- Dec 12, 2025: SEC 8-K (1.01): On December 12, 2025, Edesa Biotech, Inc. filed a prospectus supplement to increase the maximum aggregate offering amount of its common shares under the At The Market Offering Agreement with H.C. Wainwright & Co., LLC, originally dated October 4, 2024. The new maximum offering amount is set at $2,262,508. This amendment supplements the previously filed prospectus dated September 9, 2025. This strategic move allows Edesa Biotech to potentially raise additional funds for its operations and projects, enhancing its financial flexibility in a changing market environment.
- Feb 14, 2025: Raised $15.0M
- Feb 13, 2025: Edesa Biotech Announces $15.0 Million Private Placement Partnership
- Oct 31, 2024: Par Nijhawan, MD Makes $5.0 Million Strategic Investment in Edesa Biotech, Inc.
- Apr 05, 2022: Raised Undisclosed
See plans & pricing → Track Edesa Biotech’s funding, hiring, and signals — with verified contacts — on Fundz.